Game changers for new coronary pneumonia treatment already exist: rehaber plasma

Scientists are racing to develop special drugs that could help humans get rid of the new coronavirus infection, but they will have to wait 18 months to wait for them,media reported. Assuming everyone on The Planet is vaccinated, these vaccines can provide immunity to the SARS-CoV-2 virus and eradicate the disease.

Until then, doctors will use other treatments, including drugs used to treat a variety of diseases, to help patients accelerate their recovery and reduce the number of fatal cases.

Now, an ancient treatment may be working on the treatment of new coronary pneumonia, and researchers are customizing the treatment for the new coronavirus.

Game changers for new coronary pneumonia treatment already exist: rehaber plasma


We know that most of the new coronavirus infections will recover and many of them will not show any symptoms. These people have an immunity to the new coronavirus for a period of time, and this immunity can be shared by donating blood plasma. The plasma contains antibodies that fight infection, which can be used to strengthen the immune system in severely ill patients.

This treatment is not new because it has been used in the past to fight various other infectious diseases. New York is one of the places where doctors develop plasma programs to help people in need. But other medical centers in the United States and other countries have adopted similar treatments.

“We have a lot of patients who are sick. We pray that this will change the game and really accelerate the recovery of these patients,” Dr. Jeffrey Jhang of Mount Sinai Medical Systems told the media.

It is understood that the great thing about this new treatment is that it includes antibody testing of donor blood. Dr Florian Krammer, a microbiologist at Icahn College in Mount Sinai, has developed an antibody test that tells people not only if they have the right antibodies but also how many antibodies there are. In this way, doctors can collect plasma from patients who exhibit the strongest immune response to the disease.

Donors will also be tested to determine if the virus is still present in their system. This is because the patient’s new coronary pneumonia should be cured before donating plasma. At some stages of the disease, antibodies can coexist with viruses.

The problem with this treatment is that it can’t scale up as quickly as needed. Before the vaccine came out, it could become a real game-changer. More than 10,000 people responded to Mount Sinai’s call for volunteers.

The accepted person is to donate the equivalent of four doses of plasma. Then two doses were given to the seriously ill patient, and Mount Sinai has treated more than 20 of the most seriously ill patients. There may be thousands of people around the world who need such treatment. In addition, plasma can also be used as a preventive medicine for medical care workers who need to take care of patients with new coronary pneumonia on a regular basis. Johns Hopkins University is testing the plasma-based therapy, approved by the FDA last week.